Research graph
References from Transforming Hemophilia Treatment With Novel Rebalancing Agents: Clinical Studies and Practical Perspectives. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3324/haematol.2019.221093
10.3324/haematol.2019.221093 · External reference
10.1111/hae.13449
10.1111/hae.13449 · External reference
10.1111/hae.14046
10.1111/hae.14046 · External reference
10.1016/j.jtha.2024.05.026
10.1016/j.jtha.2024.05.026 · External reference
10.3324/haematol.2025.288245
10.3324/haematol.2025.288245 · External reference
10.1111/hae.14201
10.1111/hae.14201 · External reference
10.1111/hae.14866
10.1111/hae.14866 · External reference
Current Challenges in the Management of Hemophilia
2015 · External reference
10.3324/haematol.2019.239160
10.3324/haematol.2019.239160 · External reference
10.1055/s-0040-1714279
10.1055/s-0040-1714279 · External reference
10.1161/atvbaha.120.312919
10.1161/atvbaha.120.312919 · External reference
10.1111/hae.14757
10.1111/hae.14757 · External reference
10.3390/jcm10194303
10.3390/jcm10194303 · External reference
10.1182/blood.2020009217
10.1182/blood.2020009217 · External reference
10.1111/jth.14957
10.1111/jth.14957 · External reference
10.1111/jth.15506
10.1111/jth.15506 · External reference
10.1056/nejmoa2216455
10.1056/nejmoa2216455 · External reference
10.1016/j.jfma.2023.05.008
10.1016/j.jfma.2023.05.008 · External reference
10.1016/j.rpth.2025.102948
10.1016/j.rpth.2025.102948 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1182/blood.2024027468
10.1182/blood.2024027468 · External reference
Efficacy and Safety of Marstacimab Prophylaxis in Hemophilia A/B With Inhibitors: Results from the Phase 3 BASIS Trial
2025 · External reference
Unresolved reference
External reference
10.1182/blood.2024027008
10.1182/blood.2024027008 · External reference
10.1016/s2352-3026(24)00307-7
10.1016/s2352-3026(24)00307-7 · External reference
Unresolved reference
External reference
Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Switching from Emicizumab to Marstacimab: In Vitro Data and Phase 1B Study Design
2025 · External reference
10.1056/nejme2304535
10.1056/nejme2304535 · External reference
10.2147/jbm.s490588
10.2147/jbm.s490588 · External reference
Milder Clinical Presentation of Haemophilia A with Severe Deficiency of Factor VIII as Measured by One-stage Assay
2001 · External reference
10.1111/j.1365-2141.2007.06693.x
10.1111/j.1365-2141.2007.06693.x · External reference
10.1002/ajh.27602
10.1002/ajh.27602 · External reference
10.1080/17474086.2025.2519002
10.1080/17474086.2025.2519002 · External reference
10.1111/j.1365-2044.2004.03679.x
10.1111/j.1365-2044.2004.03679.x · External reference
10.1111/hae.14595
10.1111/hae.14595 · External reference
10.1016/s0140-6736(23)00284-2
10.1016/s0140-6736(23)00284-2 · External reference
10.1016/s2352-3026(23)00037-6
10.1016/s2352-3026(23)00037-6 · External reference
10.1182/blood.2023021864
10.1182/blood.2023021864 · External reference
10.1182/bloodadvances.2024013900
10.1182/bloodadvances.2024013900 · External reference
10.1016/j.rpth.2023.100179
10.1016/j.rpth.2023.100179 · External reference
New Fitusiran 10 mg Dose Increases Proportion of People with Hemophilia Within Target Antithrombin Range of 15%-35
2026 · External reference
10.1182/blood-2024-206336
10.1182/blood-2024-206336 · External reference
10.1016/j.bcmd.2020.102416
10.1016/j.bcmd.2020.102416 · External reference
Quantitative Systems Pharmacology (QSP) to Predict Thrombin Generation with Concomitant AT Lowering and Factor Replacement or Bypassing Agents
2018 · External reference
10.1016/j.htct.2024.09.949
10.1016/j.htct.2024.09.949 · External reference
10.1182/blood-2025-4850
10.1182/blood-2025-4850 · External reference
10.1111/jth.14380
10.1111/jth.14380 · External reference
10.1111/jth.15323
10.1111/jth.15323 · External reference
Management of breakthrough bleeding episodes in the phase 3 concizumab studies
2024 · External reference
10.1182/blood-2023-179739
10.1182/blood-2023-179739 · External reference
Long-Term Efficacy of Marstacimab in Participants with Severe Hemophilia A or B without Inhibitors
2025 · External reference
Unresolved reference
External reference
Outcomes by Dose Escalation Criteria in Participants with Haemophilia A or B without Inhibitors Receiving Marstacimab in the Basis Trial
2025 · External reference
Unresolved reference
External reference
10.1002/rth2.12679
10.1002/rth2.12679 · External reference
10.1182/blood-2025-3066
10.1182/blood-2025-3066 · External reference
Surgical and Medical Procedures in Participants with Haemophilia A or B without Inhibitors Receiving Marstacimab in the Basis and Open-Label Extension Trials
2025 · External reference
10.1016/s2352-3026(26)00009-8
10.1016/s2352-3026(26)00009-8 · External reference
10.1016/j.rpth.2024.102434
10.1016/j.rpth.2024.102434 · External reference
10.1111/hae.14982
10.1111/hae.14982 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
